Tetraphase Pharmaceuticals (NASDAQ:TTPH)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued on Tuesday. They currently have a $17.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 191.10% from the company’s current price.

Several other research firms have also recently issued reports on TTPH. Zacks Investment Research cut Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, October 5th. BMO Capital Markets raised their price objective on shares of Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the stock an “outperform” rating in a report on Wednesday, October 4th. ValuEngine lowered shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Needham & Company LLC reiterated a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Sunday, September 17th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $13.00 target price on shares of Tetraphase Pharmaceuticals in a report on Tuesday, September 12th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $15.15.

Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded down $0.16 during trading hours on Tuesday, hitting $5.84. The stock had a trading volume of 474,700 shares, compared to its average volume of 709,861. Tetraphase Pharmaceuticals has a 52-week low of $3.57 and a 52-week high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.63). The company had revenue of $4.10 million for the quarter, compared to analysts’ expectations of $1.59 million. Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. Tetraphase Pharmaceuticals’s quarterly revenue was up 355.6% on a year-over-year basis. During the same period last year, the firm earned ($0.58) earnings per share. sell-side analysts anticipate that Tetraphase Pharmaceuticals will post -2.88 EPS for the current fiscal year.

In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 8,750 shares of Tetraphase Pharmaceuticals stock in a transaction that occurred on Tuesday, October 31st. The shares were sold at an average price of $6.03, for a total value of $52,762.50. Following the completion of the sale, the insider now owns 8,750 shares of the company’s stock, valued at approximately $52,762.50. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director L Patrick Gage bought 3,880 shares of the business’s stock in a transaction on Wednesday, November 29th. The stock was bought at an average cost of $6.45 per share, with a total value of $25,026.00. Following the transaction, the director now owns 38,880 shares in the company, valued at approximately $250,776. The disclosure for this purchase can be found here. 5.50% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the business. California Public Employees Retirement System grew its position in shares of Tetraphase Pharmaceuticals by 2.0% during the 2nd quarter. California Public Employees Retirement System now owns 242,200 shares of the biopharmaceutical company’s stock valued at $1,727,000 after acquiring an additional 4,800 shares during the period. Schwab Charles Investment Management Inc. lifted its stake in shares of Tetraphase Pharmaceuticals by 6.5% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 128,807 shares of the biopharmaceutical company’s stock valued at $1,184,000 after buying an additional 7,866 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Tetraphase Pharmaceuticals by 16.4% during the 1st quarter. Vanguard Group Inc. now owns 1,638,789 shares of the biopharmaceutical company’s stock valued at $15,061,000 after buying an additional 230,420 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Tetraphase Pharmaceuticals by 17.0% during the 1st quarter. Geode Capital Management LLC now owns 313,390 shares of the biopharmaceutical company’s stock valued at $2,880,000 after buying an additional 45,554 shares in the last quarter. Finally, EcoR1 Capital LLC purchased a new position in shares of Tetraphase Pharmaceuticals during the 2nd quarter valued at $4,516,000. 58.19% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/12/06/tetraphase-pharmaceuticals-ttph-receives-buy-rating-from-hc-wainwright.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.